"ME-401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-CELL LYMPHOID MALIGNANCIES" by R.G. Ghalie

Selected Works of John M. Pagel, MD, PhD

Article

ME-401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-CELL LYMPHOID MALIGNANCIES

Hematological Oncology (2017)

R.G. Ghalie
J.M. Pagel
J. Soumerai
A. Iasonos
K. Patel
O. Moreno
T. Butler
A.D. Zelenetz

Link

Disciplines

Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

June 1, 2017

DOI

10.1002/hon.2439_184

Citation Information

R.G. Ghalie, J.M. Pagel, J. Soumerai, A. Iasonos, et al.. "ME-401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-CELL LYMPHOID MALIGNANCIES" Hematological Oncology Vol. 35 (2017) p. 407 - 407
Available at: http://works.bepress.com/john-pagel/307/